association (references)

References for: association

Full identifier: http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association

Nanopublication	Part	Subject	Predicate	Object	Published By	Published On
http://purl.org/np/RAQxql8Xc2... RAQxql8Xc2	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#type type	http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement	Leoni Bücken	2021-08-25T11:33:11.099Z
http://purl.org/np/RAQxql8Xc2... RAQxql8Xc2	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/2000/01/rdf-schema#label label	"Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension, or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [ 4.1 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [ 4.2 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients [See Dosage and Administration section"	Leoni Bücken	2021-08-25T11:33:11.099Z
http://purl.org/np/RAQxql8Xc2... RAQxql8Xc2	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#object object	http://purl.obolibrary.org/obo/DOID_10763 DOID_10763	Leoni Bücken	2021-08-25T11:33:11.099Z
http://purl.org/np/RAQxql8Xc2... RAQxql8Xc2	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate	https://w3id.org/biolink/vocab/treats treats	Leoni Bücken	2021-08-25T11:33:11.099Z
http://purl.org/np/RAQxql8Xc2... RAQxql8Xc2	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject	https://identifiers.org/drugbank:DB00388 drugbank:DB00388	Leoni Bücken	2021-08-25T11:33:11.099Z
http://purl.org/np/RAQxql8Xc2... RAQxql8Xc2	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/provided_by provided_by	https://w3id.org/um/NeuroDKG NeuroDKG	Leoni Bücken	2021-08-25T11:33:11.099Z
http://purl.org/np/RAQxql8Xc2... RAQxql8Xc2	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/relation relation	https://schema.org/MedicalContraindication MedicalContraindication	Leoni Bücken	2021-08-25T11:33:11.099Z